Site Group Page
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Site Group Page
 

Site Information
RIPK2 (human) S176-p KWRMMSLsQSRSSKS 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31
RIPK2 (mouse) S176-p KWRMMSLsQSRSYKS 30
RIPK2 (rat) S176-p KWRMMSLsQSRSYKS

References

1

Zhou H, et al. (2013) Toward a comprehensive characterization of a human cancer cell phosphoproteome. J Proteome Res 12, 260-71
23186163   Curated Info

2

Stokes MP, et al. (2012) PTMScan Direct: Identification and Quantification of Peptides from Critical Signaling Proteins by Immunoaffinity Enrichment Coupled with LC-MS/MS. Mol Cell Proteomics 11, 187-201
22322096   Curated Info

3

(2011) CST Curation Set: 10919; Year: 2011; SILAC: N; Biosample/Treatment: NCI-H1944(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

4

(2011) CST Curation Set: 10899; Year: 2011; SILAC: N; Biosample/Treatment: NCI-H1437(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

5

(2011) CST Curation Set: 10907; Year: 2011; SILAC: N; Biosample/Treatment: NCI-H2073(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

6

(2010) CST Curation Set: 10031; Year: 2010; SILAC: N; Biosample/Treatment: HCC827(cell line)/untreated; Disease: -; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

7

(2010) CST Curation Set: 9985; Year: 2010; SILAC: N; Biosample/Treatment: NCI-H441(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

8

(2010) CST Curation Set: 9986; Year: 2010; SILAC: N; Biosample/Treatment: NCI-H441(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

9

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

10

(2010) CST Curation Set: 9760; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

11

(2010) CST Curation Set: 9762; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

12

(2010) CST Curation Set: 9755; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

13

(2010) CST Curation Set: 9765; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

14

(2010) CST Curation Set: 9756; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

15

(2010) CST Curation Set: 9757; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

16

(2010) CST Curation Set: 9768; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

17

(2010) CST Curation Set: 9770; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

18

(2010) CST Curation Set: 9772; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

19

(2010) CST Curation Set: 9752; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

20

(2010) CST Curation Set: 9758; Year: 2010; SILAC: N; Biosample/Treatment: lung(tissue)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

21

(2010) CST Curation Set: 9373; Year: 2010; SILAC: N; Biosample/Treatment: MKN-45(cell line)/Su11274; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

22

(2010) CST Curation Set: 9279; Year: 2010; SILAC: N; Biosample/Treatment: MKN-45(cell line)/DMSO & Su11274; Disease: gastric carcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

23

(2010) CST Curation Set: 9240; Year: 2010; SILAC: N; Biosample/Treatment: NCI-H1703(cell line)/untreated; Disease: non-small cell lung cancer; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

24

(2010) CST Curation Set: 9243; Year: 2010; SILAC: N; Biosample/Treatment: HeLa(cell line)/UV; Disease: cervical adenocarcinoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-[sty](phosphorylation)
Curated Info

25

(2010) CST Curation Set: 8837; Year: 2010; SILAC: N; Biosample/Treatment: K562(cell line)/untreated; Disease: chronic myelogenous leukemia; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-pTyr Antibody Used to Purify Peptides prior to MS2: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

26

Olsen JV, et al. (2010) Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. Sci Signal 3, ra3
20068231   Curated Info

27

Oppermann FS, et al. (2009) Large-scale proteomics analysis of the human kinome. Mol Cell Proteomics 8, 1751-64
19369195   Curated Info

28

Daub H, et al. (2008) Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol Cell 31, 438-48
18691976   Curated Info

29

Matsuoka S, et al. (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316, 1160-6
17525332   Curated Info

30

Dorsch M, et al. (2006) Identification of a regulatory autophosphorylation site in the serine-threonine kinase RIP2. Cell Signal 18, 2223-9
16824733   Curated Info

31

(2006) CST Curation Set: 1092; Year: 2006; SILAC: N; Biosample/Treatment: M059J(cell line)/UV; Disease: glioblastoma; Specificity of Antibody Used to Purify Peptides prior to MS2: anti-(s/t)Q(phosphorylation) Antibody Used to Purify Peptides prior to MS2: Phospho-(Ser/Thr) ATM/ATR Substrate Antibody Cat#: 2851
Curated Info

Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.